Literature DB >> 7755612

Characterization of recombinant human liver thermolabile phenol sulfotransferase with minoxidil as the substrate.

P E Kudlacek1, D L Clemens, R J Anderson.   

Abstract

Minoxidil, a potent antihypertensive agent and hair growth stimulator, is metabolized by phenol sulfotransferase to its activated form, minoxidil sulfate. The thermostable form of phenol sulfotransferase was reported to be the enzyme that catalyzed the reaction. Our previous findings with partially purified human platelet preparations indicated that the thermolabile form of phenol sulfotransferase also catalyzed the sulfation of minoxidil. To confirm and to characterize precisely the activity of thermolabile phenol sulfotransferase toward minoxidil, we investigated the ability of the enzyme expressed from a human liver cDNA clone to sulfate minoxidil during testing of thermal stability and of inhibition by 2,6-dichloro-4-nitrophenol and NaCl. The cDNA encoded thermolabile phenol sulfotransferase activity assayed with minoxidil behaved in the same fashion as the activity measured with dopamine, a finding that confirmed that this enzyme activity sulfated minoxidil. Thus, thermolabile phenol sulfotransferase must be taken into account with the thermostable enzyme when estimating the human tissue sulfotransferase contribution to minoxidil sulfation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7755612     DOI: 10.1006/bbrc.1995.1670

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Expression and functional activities of selected sulfotransferase isoforms in BeWo cells and primary cytotrophoblast cells.

Authors:  Pallabi Mitra; Kenneth L Audus
Journal:  Biochem Pharmacol       Date:  2009-07-30       Impact factor: 5.858

2.  Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms.

Authors:  Tiby B Joseph; Stephen W J Wang; Xing Liu; Kaustubh H Kulkarni; Jingrong Wang; Haiyan Xu; Ming Hu
Journal:  Mol Pharm       Date:  2007 Nov-Dec       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.